Search TGTX
TG THERAPEUTICS, INC.
Nasdaq · CIK 1001316
Last close54.29
Daily change+0.67 (1.25%)
10 Years gain+596.03%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TGTX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
65.9Momentum
100.0Acceleration
90.1Confidence
91.0Annual Revenue10
Quarterly Revenue32
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality14.3 / 25
Capital Efficiency15.9 / 20
Balance Sheet6.7 / 15
Shareholder Economics2.4 / 10
Forward Indicators1.7 / 5
Signals
Operating leverageOperating margin improved by 10.1012 percentage points.
ROIC expansionROIC improved by 5.0312 percentage points.
Share count reductionDiluted share count declined 3.3712%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 4.9672 percentage points.
Key Metrics
Revenue Growth TTM118.95%OK
Revenue CAGR 3Y504.86%OK
Gross Margin83.73%OK
Operating Margin16.13%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC13.82%OK
Incremental Operating Margin 3Y52.45%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-3.37%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $616.29M | $515.57M | $123.32M | -$24.77M | -$24.99M | 83.66% | 20.01% | -4.05% | 17.67% | 161.41M |
| 2025 FY Dec 31, 2024 | $329.00M | $290.52M | $41.93M | -$40.52M | -$40.56M | 88.3% | 12.74% | -12.33% | 38.46% | 160.34M |
| 2025 FY Dec 31, 2023 | $233.66M | $219.53M | $20.63M | -$31.41M | -$31.41M | 93.95% | 8.83% | -13.44% | 349.92% | 148.51M |
| 2024 FY Dec 31, 2022 | $2.79M | $2.52M | -$218.32M | -$176.17M | -$176.18M | 90.48% | -7,838.99% | -6,326.18% | n/a | 135.41M |
| 2023 FY Dec 31, 2021 | $6.69M | $5.90M | -$344.77M | -$295.63M | -$296.04M | 88.19% | -5,154.28% | -4,425.7% | n/a | 132.22M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $748.11M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-025955, 0001437749-25-033363 |
| Revenue Growth TTM | 118.95% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-025955, 0001437749-25-033363 |
| Revenue CAGR 3Y | 504.86% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-006133 |
| Revenue CAGR 5Y | 426.73% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-006133 |
| Gross Profit CAGR 3Y | 489.25% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-006133 |
| Operating Income Growth | 485.75% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001437749-26-025955, 0001437749-25-033363 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 83.73% | Gross Profit / Revenue | OK | 0001437749-26-025955, 0001437749-25-033363 |
| Operating Margin | 16.13% | Operating Income / Revenue | OK | 0001437749-26-025955, 0001437749-25-033363 |
| ROIC | 13.82% | NOPAT / Average Invested Capital | OK | 0001437749-26-025955, 0001437749-25-033363 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-025955 |
| Current Ratio | 4.27x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.74x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-025955 |
| Revenue per Diluted Share | $4.76 | Revenue / Diluted Shares | OK | 0001437749-26-025955, 0001437749-25-033363 |